Robert H Collins

9PUBLICATIONS
88CO-AUTHORS
Nanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular medicineGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 09, 2025
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants.

Jinsuke Nishino, Wenhuo Hu, Ashwin Kishtagari

|Feb 07, 2024
Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.

Eunice S Wang, Aaron D Goldberg, Martin Tallman

|Aug 17, 2023
Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform.

Mohammad Faizan Zahid, Kelsey Moriarty, Courtney Dryden

|Oct 12, 2022
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.

Junhua Lyu, Yuxuan Liu, Lihu Gong

|Oct 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.

Amy Burd, Ross L Levine, Amy S Ruppert

|Apr 11, 2019
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Daniel A Pollyea, Martin S Tallman, Stéphane de Botton

Pageof 2

Frequent Collaborators

3 joint publications

Brian J Druker

3 joint publications

Stephen S Chung

3 joint publications

Yazan F Madanat

2 joint publications

Prapti Patel